Heghine Khachatryan: Celebrating One Hundred Years of von Willebrand Disease with EHC
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared EHC’s post on LinkedIn:
“One hundred years after the first description of von Willebrand disease, the field continues to evolve from clinical observation to precision diagnostics, molecular understanding, and targeted therapies.
What began in 1926 as the description of a hereditary bleeding disorder has now become a global effort focused on improving diagnosis, access to care, and quality of life for patients worldwide.
Despite major scientific advances, many patients – especially women and individuals in low-resource settings – remain underdiagnosed or untreated.
Continued education, awareness, laboratory development, and international collaboration remain essential for the next century of progress in bleeding disorders care.
Congratulations to the European von Willebrand Disease Community and EHC for highlighting this important milestone in hematology and hemostasis history.”
EHC – European Haemophilia Consortium shared a post on LinkedIn:
“100 years of von Willebrand Disease: looking back, moving forward
In 1926, Erik Adolf von Willebrand first described a hereditary bleeding disorder that would later bear his name:
von Willebrand Disease (VWD).
One hundred years later, we mark this important milestone.
As the EHC’s VWD Committee, we will be reflecting on this anniversary over the coming months, tracing developments in knowledge and care since that first description in 1926.
Much has been achieved over the past century:
insight into underlying mechanisms has grown, diagnostics have improved, and treatments have advanced.
Yet VWD remains a relatively unknown clotting disorder, frequently recognised late or not at all, leading to delays that impact patients’ quality of life.
Treatment options also continue to lag behind, especially compared to haemophilia.
With this campaign, we look not only back but also forward, aiming for greater awareness, timely recognition, and further improvement of care.
Swipe through the images to explore key milestones from 1926 to 2026, and follow along as we share a new chapter of the VWD story each month throughout 2026.”

Other posts featuring Heghine Khachatryan and EHC – European Haemophilia Consortium on Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?